ASP Isotopes Inc. (NASDAQ:ASPI) Shares Purchased by Northern Trust Corp

Northern Trust Corp lifted its position in shares of ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) by 15.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 435,688 shares of the company's stock after acquiring an additional 58,525 shares during the quarter. Northern Trust Corp owned 0.61% of ASP Isotopes worth $1,974,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in ASPI. CenterBook Partners LP acquired a new stake in shares of ASP Isotopes during the 4th quarter valued at approximately $6,800,000. Rovida Investment Management Ltd acquired a new position in ASP Isotopes during the fourth quarter worth $990,000. JPMorgan Chase & Co. boosted its position in ASP Isotopes by 854.6% during the fourth quarter. JPMorgan Chase & Co. now owns 211,893 shares of the company's stock worth $960,000 after purchasing an additional 189,697 shares in the last quarter. Geode Capital Management LLC grew its holdings in ASP Isotopes by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 1,175,450 shares of the company's stock valued at $5,326,000 after purchasing an additional 57,027 shares during the last quarter. Finally, Virtu Financial LLC increased its position in shares of ASP Isotopes by 403.0% in the fourth quarter. Virtu Financial LLC now owns 58,812 shares of the company's stock valued at $266,000 after buying an additional 47,119 shares in the last quarter. 16.80% of the stock is owned by hedge funds and other institutional investors.

ASP Isotopes Price Performance

Shares of NASDAQ:ASPI traded up $0.01 on Friday, hitting $7.66. The company had a trading volume of 267,455 shares, compared to its average volume of 2,329,331. The company has a current ratio of 7.55, a quick ratio of 7.54 and a debt-to-equity ratio of 0.80. The company has a market cap of $574.97 million, a PE ratio of -12.52 and a beta of 3.40. ASP Isotopes Inc. has a 52-week low of $1.86 and a 52-week high of $9.33. The business has a 50 day moving average of $5.86 and a 200 day moving average of $5.47.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group lifted their target price on shares of ASP Isotopes from $8.50 to $11.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st.

Insider Buying and Selling

In other news, CEO Paul Elliot Mann sold 316,666 shares of the company's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $5.62, for a total transaction of $1,779,662.92. Following the completion of the transaction, the chief executive officer now owns 7,315,454 shares of the company's stock, valued at $41,112,851.48. This represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Robert Ainscow sold 66,666 shares of the firm's stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total transaction of $383,329.50. Following the completion of the sale, the chief operating officer now directly owns 1,553,326 shares in the company, valued at $8,931,624.50. This represents a 4.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 766,667 shares of company stock worth $4,358,502. 21.40% of the stock is owned by insiders.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.